Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07592910 Enzalutamide Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07592910 clinical trial report covering Enzalutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07594145 Finerenone Diabetes Mellitus, Type 1 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07594145 clinical trial report covering Finerenone, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261957 QX-008N Nasal Polyps Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
CTR20261957 clinical trial report covering QX-008N, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07595705 Ascorbic Acid Hyperpigmentation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07595705 clinical trial report covering Ascorbic Acid, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2051260041 Olutasidenib IDH1 Mutation Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
JPRN-jRCT2051260041 clinical trial report covering Olutasidenib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07594925 Sintilimab MSS/pMMR/MSI-L Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07594925 clinical trial report covering Sintilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600124919 Albumin-Bound Paclitaxel Squamous Cell Carcinoma of the Larynx Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124919 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07594899 Lenalidomide Large B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07594899 clinical trial report covering Lenalidomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07595770 Albumin-Bound Paclitaxel Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07595770 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07596121 Serplulimab Non-Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07596121 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07596342 Sodium Oxybate Dyssomnias Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07596342 clinical trial report covering Sodium Oxybate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07597629 SYS6023 Locally Advanced Unresectable Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07597629 clinical trial report covering SYS6023, Phase 2, endpoints, sponsor, geography, readout timing and development white space.